<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02363322</url>
  </required_header>
  <id_info>
    <org_study_id>150083</org_study_id>
    <secondary_id>15-I-0083</secondary_id>
    <nct_id>NCT02363322</nct_id>
  </id_info>
  <brief_title>Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection</brief_title>
  <official_title>A Multicenter Randomized Safety and Efficacy Study of Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Ministry of Health and Social Welfare, Liberia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ministry of Health and Sanitation, Sierra Leone</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Ministry of Health and Public Hygiene, Guinea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Ebola is a viral infection that can spread quickly and causes life-threatening disease.
      Right now there is an Ebola outbreak in many countries in West Africa. There are no approved
      treatments for Ebola. But possible treatments are being developed. Researchers need to study
      these treatments to see if they help people get better.

      Objective:

      - To identify possible Ebola treatments. Also, to learn if adding 1 or more experimental
      drugs to advanced Ebola care can reduce the risk of death.

      Eligibility:

      - People who have recently been diagnosed with Ebola, usually by a test called the Polymerase
      Chain Reaction (PCR), and have been hospitalized in an isolation unit for treatment.

      Design:

        -  Participants will be randomly assigned to Group A or B. Both groups will get advanced
           level care. One group will also get an experimental drug.

        -  Participants may have blood tests. They may have another PCR test.

        -  Researchers will try to learn how the participant got Ebola.

        -  Participants put in the experimental drug group may start taking medicine within 24
           hours of enrollment. It may be given by mouth or intravenously. Additional doses may be
           needed.

        -  Participants may have a series of timed blood tests over the first 24 to 48 hours after
           they take the medicine.

        -  Blood will be drawn frequently. Other body fluids (urine, stool, vaginal fluid, etc.)
           may also be collected.

        -  Participants will be followed for up to 60 days. They may be evaluated for any long-term
           effects of the experimental treatment(s). They may be asked to return for 1 or more
           outpatient visits.

        -  For consenting participants, follow-up will be extended for up to one full year past Day
           58 with contact/visits every 1-3 months to assess for a history of signs or symptoms
           potentially consistent with late onset of virologic relapse syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ebolaviruses (EBOV) are members of the Filoviridae and are known primarily as the underlying
      cause of severe viral hemorrhagic fevers with disturbingly high case fatality rates. Between
      1994 and the present, there have been many EBOV outbreaks affecting mostly central Africa,
      with 2 large outbreaks in 1995 in Kikwit, Democratic Republic of Congo (DRC), and in Gulu,
      Uganda in 2000-2001. However, the 2014 West African outbreak significantly exceeds all
      previous outbreaks in geographic range, number of patients affected, and in disruption of
      typical activities of civil society.

      There is strong consensus that the most important element necessary to improve survival from
      Ebola infection is the provision of full hemodynamic support in the form of aggressive fluid
      replacement, ability to diagnose and correct severe metabolic derangements, and other
      standards of modern medical care available in resource-rich environments. However, against
      this background, a small series of investigational agents or interventions have also been
      proposed as putative antiviral strategies of potential utility in treating this infection.
      Unfortunately, phase 1/2 data supporting the safety and efficacy of these agents is generally
      lacking, and thus there should be equipoise as to which, if any, of these interventions
      should be utilized in the treatment of severe infection.

      In this multicenter randomized trial, we propose a flexible trial design with frequent
      interim monitoring to facilitate early elimination of poorly performing treatments as well as
      the introduction of new candidate therapies. The trial allows for a series of pairwise
      comparisons of novel interventions against a background of optimized medical care, with the
      goal of determining whether one or more of these interventions can improve the mortality over
      that achievable through optimized standard-of- care (oSOC) alone. The primary endpoint of
      this trial will be comparative mortality at Day 28, with a number of secondary endpoints that
      hopefully will generate generalizable knowledge about the relative safety and antiviral
      activity of these adjunctive interventions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2015</start_date>
  <completion_date type="Actual">December 31, 2017</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Death at Day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With ZMapp Infusion-related Adverse Events</measure>
    <time_frame>10 Days</time_frame>
    <description>Adverse events related to ZMapp infusions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Viral Load</measure>
    <time_frame>28 days</time_frame>
    <description>Time to viral clearance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Ebola Virus Infection</condition>
  <arm_group>
    <arm_group_label>A/Current Standard of Care Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A/Current Standard of Care Alone: Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B/Current Standard of Care Plus ZMapp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B/Current Standard of Care Plus ZMapp: ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMapp 50mg/kg IV administered every third day for 3 infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/Current Standard of Care Plus ZMapp</intervention_name>
    <description>Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
    <arm_group_label>B/Current Standard of Care Plus ZMapp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>A/Current Standard of Care Alone</intervention_name>
    <description>Optimized standard of care for Ebola virus infection</description>
    <arm_group_label>A/Current Standard of Care Alone</arm_group_label>
    <arm_group_label>B/Current Standard of Care Plus ZMapp</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Males or females with documented positive PCR for Ebola virus infection within 10 days
             of enrollment

          -  Willingness of study participant to accept randomization to any assigned treatment arm

          -  Access to oSOC

          -  All males and females of childbearing potential, must be willing to use highly
             effective methods of contraception [e.g. absolute abstinence from potentially
             reproductive sexual activity, hormonal, surgical or multiple barrier/combined], from
             time of enrollment for the duration of study participation.

          -  Must agree not to enroll in another study of an investigational agent prior to
             completion of last required protocol visit (Day 58)

          -  Ability to provide informed consent personally, or by a legally-authorized [per
             applicable local laws and regulations] representative [LAR] if the patient is unable
             to do so.

        EXCLUSION CRITERIA:

          -  Any medical condition that, in the opinion of the site investigator, would place the
             patient at an unreasonably increased risk through participation in this study,
             including any past or concurrent conditions that would preclude randomization to one
             or more of the assigned treatment arms.

          -  Prior treatment with any investigational antiviral drug therapy against Ebola
             infection other than experimental vaccines, within 5 half-lives or 30 days, whichever
             is longer, prior to enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard T Davey, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Allergy and Infectious Diseases (NIAID)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTE Forecariah</name>
      <address>
        <city>Forecariah</city>
        <country>Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monrovia Medical Unit</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ELWA III Hospital</name>
      <address>
        <city>Paynesville</city>
        <country>Liberia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Police Training School 1 (PTS1), Western Rural District</name>
      <address>
        <city>Freetown</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emergency Ebola Treatment Unit</name>
      <address>
        <city>Goderich</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Police Training School 2</name>
      <address>
        <city>Hastings</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese Friendship Hospital</name>
      <address>
        <city>Jui</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Corps (IMC) Kambia</name>
      <address>
        <city>Kambia</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Corps (IMC) Lunsar</name>
      <address>
        <city>Port Loko</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adventist Development and Relief Ebola Treatment Unit</name>
      <address>
        <city>Waterloo</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Guinea</country>
    <country>Liberia</country>
    <country>Sierra Leone</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2015-I-0083.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014 Oct 1;312(13):1299-300. doi: 10.1001/jama.2014.12867.</citation>
    <PMID>25211645</PMID>
  </reference>
  <reference>
    <citation>Kanapathipillai R. Ebola virus disease--current knowledge. N Engl J Med. 2014 Sep 25;371(13):e18. doi: 10.1056/NEJMp1410741.</citation>
    <PMID>25251632</PMID>
  </reference>
  <reference>
    <citation>Piot P, Muyembe JJ, Edmunds WJ. Ebola in west Africa: from disease outbreak to humanitarian crisis. Lancet Infect Dis. 2014 Nov;14(11):1034-1035. doi: 10.1016/S1473-3099(14)70956-9. Epub 2014 Oct 1.</citation>
    <PMID>25282665</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 13, 2015</study_first_submitted>
  <study_first_submitted_qc>February 13, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2015</study_first_posted>
  <results_first_submitted>August 7, 2018</results_first_submitted>
  <results_first_submitted_qc>April 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 14, 2019</results_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medical Countermeasures</keyword>
  <keyword>VHF</keyword>
  <keyword>EVD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 22, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT02363322/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Beginnning in March 2015 through November 2015 a total of 72 patients were enrolled at sites in Liberia, Sierra Leone, Guinea, and the United States.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>A/Current Standard of Care Alone</title>
          <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting
Treatment A: Optimized standard of care for Ebola virus infection</description>
        </group>
        <group group_id="P2">
          <title>B/Current Standard of Care Plus ZMapp</title>
          <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A/Current Standard of Care Alone</title>
          <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
        </group>
        <group group_id="B2">
          <title>B/Current Standard of Care Plus ZMapp</title>
          <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="36"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.9" spread="16.4"/>
                    <measurement group_id="B2" value="24.3" spread="18.3"/>
                    <measurement group_id="B3" value="26.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liberia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Guinea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sierra Leone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mortality</title>
        <description>Death at Day 28</description>
        <time_frame>28 days</time_frame>
        <population>Seven of the eight deaths recorded in ZMapp recipients occurred before day 4, before the second of three planned infusions of ZMapp. The exception was one patient who received a second infusion on day 4 and died later that day. In the group that received the current standard of care alone, all 13 deaths occurred during the first 8 days of follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>A/Current Standard of Care Alone</title>
            <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
          </group>
          <group group_id="O2">
            <title>B/Current Standard of Care Plus ZMapp</title>
            <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>Death at Day 28</description>
          <population>Seven of the eight deaths recorded in ZMapp recipients occurred before day 4, before the second of three planned infusions of ZMapp. The exception was one patient who received a second infusion on day 4 and died later that day. In the group that received the current standard of care alone, all 13 deaths occurred during the first 8 days of follow-up</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With ZMapp Infusion-related Adverse Events</title>
        <description>Adverse events related to ZMapp infusions</description>
        <time_frame>10 Days</time_frame>
        <population>Arm A Received the Current Standard of Care Alone and not the ZMapp infusion</population>
        <group_list>
          <group group_id="O1">
            <title>A/Current Standard of Care Alone</title>
            <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
          </group>
          <group group_id="O2">
            <title>B/Current Standard of Care Plus ZMapp</title>
            <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With ZMapp Infusion-related Adverse Events</title>
          <description>Adverse events related to ZMapp infusions</description>
          <population>Arm A Received the Current Standard of Care Alone and not the ZMapp infusion</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elevation in fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachycardia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tachypnea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Confusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seizure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Difficulty Breathing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Agitation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Viral Load</title>
        <description>Time to viral clearance</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>A/Current Standard of Care Alone</title>
            <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
          </group>
          <group group_id="O2">
            <title>B/Current Standard of Care Plus ZMapp</title>
            <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Viral Load</title>
          <description>Time to viral clearance</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="0" upper_limit="28"/>
                    <measurement group_id="O2" value="9" lower_limit="0" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months, from March 2015 through November 2015</time_frame>
      <desc>Only Serious Adverse Events and Infusion related events were recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>A/Current Standard of Care Alone</title>
          <description>Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting</description>
        </group>
        <group group_id="E2">
          <title>B/Current Standard of Care Plus ZMapp</title>
          <description>ZMapp (Trademark) + Optimized standard of care to include aggressive fluid resuscitation, hemodynamic support, and other interventions available in an optimized care setting.
ZMApp: Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Death due to EVD</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Multi-organ failure due to EVD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Death due to sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hospitalization with febrile illness (malaria)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Generalized seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Death due to Hypotensive Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock due to acute hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Arterial Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Elevation in Fever</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tachypnea</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Difficulty Breathing</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_at_risk="35"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the severity of the underlying illness (Ebola infection) only infusion-related adverse events were captured.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Richard T. Davey, Jr.</name_or_title>
      <organization>NIAID/LIR</organization>
      <phone>301-496-8029</phone>
      <email>rdavey@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

